Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Monograph 'Disruption' Could Ride Along With PDUFA Reauthorization – CHPA Exec

This article was originally published in The Pink Sheet Daily

Executive Summary

Changing the monograph process is an area "where disruption can be positive," CEO Scott Melville says at CHPA conference. Best chance for monograph reform could be tying it to user fee reauthorization, but that could be a lengthy process.

You may also be interested in...



Codeine Concerns Cough Up FDA's OTC Monograph Problems

Pew Charitable Trusts joins CHPA, medical groups in urging Congress to authorize moving the US monograph system to an administrative process and to authorize a monograph user fee program.

Codeine Concerns Cough Up FDA's OTC Monograph Problems

Pew Charitable Trusts joins CHPA, medical groups in urging Congress to authorize moving the US monograph system to an administrative process and to authorize a monograph user fee program.

CBD Trademarks Remain Under Wraps In US As Brands Blanket Supplement Market

USPTO appeals board rejects requests by Charlotte's Web marketer in June and the Natural Leaf brand owner in September for trademarks. Those decisions sustain USPTO policy that even though FDA allows sales of food, supplements and other non-drug products subject to its oversight that contain hemp-derived CBD, the products are unlawful and trademarking brands for them is prohibited.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel